It gives me great pleasure to present this 2021-22 Annual Report on behalf of the Rosalind and Morris Goodman Cancer Institute (GCI). As we reflect on the growth and development of our Institute, we see how the many outstanding discoveries of our researchers have shaped modern cancer research at McGill and around the world. From the first cancer biomarker to unlocking the therapeutic potential of RNA, our legacy of ground-breaking research is both a source of pride and the foundation of our current programs.
This year has been another great success for our principal investigators, trainees and staff, filled with major accomplishments and important scientific advances. New generations of talented and motivated scientists are building on the excellence of GCI research leaders, pushing the boundaries to discover what drives cancer and find new and better treatments. We continue to look outward, bringing diverse scientific disciplines together and serving as a hub for leading researchers and clinicians at McGill, throughout Canada and internationally.
The generosity and commitment of our community is essential to the pursuit of the GCI’s mission. We are extremely grateful to all the individuals and organizations that have supported the GCI and its predecessors over the past 44 years. With your sustained support, we will overcome cancer.
Morag Park, C.Q., Ph.D., FRSC, FCAHS
Director, Rosalind and Morris Goodman Cancer Institute
Diane and Sal Guerrera Chair in Cancer Genetics
Distinguished James McGill Professor, Depts. of Oncology,
Biochemistry and Medicine, McGill University